Patient Square Capital LP — 13F Holdings & Portfolio
CIK 1819257 · latest 13F-HR filed 2026-08-12
Patient Square Capital LP manages $645.5M in 13F-reported U.S. long-equity assets across 23 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ROIV (43.97%), RVMD (8.01%), MIRM (4.72%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 12; 9 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-12
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ROIVANT SCIENCES LTD$57.7M +25.5%
- ABIVAX SA$14.0M +103.8%
- PHARVARIS N V$9.3M +66.7%
- MIRUM PHARMACEUTICALS INC$9.2M +43.5%
- ARCUS BIOSCIENCES INC$6.8M +160.4%
Top Trims
- COGENT BIOSCIENCES INC-$6.5M -28.3%
- ARGENX SE-$5.5M -20.4%
- KYMERA THERAPEUTICS INC-$2.9M -34.6%
- BELITE BIO INC-$1.7M -9.0%
New Positions
- REVOLUTION MEDICINES INC$51.7M
- UNITED THERAPEUTICS CORP DEL$20.1M
- BIONTECH SE$12.5M
- C4 THERAPEUTICS INC$7.5M
- INVENTIVA SA$7.4M
Exited Positions
- INSMED INC$25.8M
- LEGEND BIOTECH CORP$17.9M
- NEKTAR THERAPEUTICS$15.1M
- CELCUITY INC$10.8M
- MERCK & CO INC$9.6M
Patient Square Capital LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $283.9M | 43.97% | 8,020,928 | SH |
| 2 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $51.7M | 8.01% | 276,000 | SH |
| 3 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $30.5M | 4.72% | 260,500 | SH |
| 4 | ABIVAX SA | ABVX | 00370M103 | $27.5M | 4.26% | 206,500 | SH |
| 5 | BEONE MEDICINES LTD | ONC | 07725L102 | $25.7M | 3.97% | 90,020 | SH |
| 6 | PHARVARIS N V | PHVS | N69605108 | $23.2M | 3.60% | 671,209 | SH |
| 7 | ARGENX SE | ARGX | 04016X101 | $21.3M | 3.31% | 23,000 | SH |
| 8 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $20.1M | 3.12% | 37,120 | SH |
| 9 | BELITE BIO INC | BLTE | 07782B104 | $16.9M | 2.62% | 110,000 | SH |
| 10 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $16.4M | 2.55% | 425,000 | SH |
| 11 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $14.9M | 2.31% | 909,474 | SH |
| 12 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $13.3M | 2.06% | 220,000 | SH |
| 13 | BIONTECH SE | BNTX | 09075V102 | $12.5M | 1.94% | 134,429 | SH |
| 14 | ARCUS BIOSCIENCES INC | RCUS | 03969F109 | $11.0M | 1.70% | 355,800 | SH |
| 15 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $10.8M | 1.67% | 212,500 | SH |
| 16 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $10.5M | 1.63% | 108,000 | SH |
| 17 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $10.5M | 1.63% | 5,050,000 | SH |
| 18 | EYEPOINT INC | EYPT | 30233G209 | $10.3M | 1.59% | 720,000 | SH |
| 19 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $9.7M | 1.50% | 370,000 | SH |
| 20 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $7.5M | 1.16% | 1,608,815 | SH |
| 21 | INVENTIVA SA | IVA | 46124U107 | $7.4M | 1.15% | 1,967,171 | SH |
| 22 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $5.4M | 0.84% | 47,500 | SH |
| 23 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $4.4M | 0.68% | 175,050 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-12 | $645.5M | 23 | 0001819257-26-000005 |
| 2026-03-31 | 2026-05-15 | $563.6M | 29 | 0001819257-26-000003 |
| 2025-12-31 | 2026-02-12 | $467.1M | 28 | 0001819257-26-000002 |
| 2025-09-30 | 2025-11-10 | $373.9M | 24 | 0001819257-25-000002 |
MENLO PARK, CA 94025